August 1997
Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS33
Academic Journal
Presents an abstract of the research manuscript `The morphology of t(15;17) APL with cytogenetic or molecular genetic evidence for the diagnosis - additional variants of APL,' by P.B. Neame, P. Soamboonsrup et al from the McMaster University. Acute promyelocytic leukemia (APL).


Related Articles

  • What happens subsequently in AML when cytogenetic abnormalities persist at bone marrow harvest? Results of the 10th UK MRC AML Trial. Grimwade, D; Walker, H; Oliver, F; Wheatley, K; Clack, R; Burnett, A; Goldstone, A // Bone Marrow Transplantation;6/1/97, Vol. 19 Issue 11, p1117 

    Cytogenetic analysis performed at diagnosis is widely recognised to provide one of the most valuable prognostic indicators in AML. Yet any role for this technique in residual disease assessment, particularly in the context of subsequent transplantation procedures has been incompletely explored....

  • Gene expression profiling in MDS and AML: potential and future avenues. Theilgaard-Mönch, K.; Boultwood, J.; Ferrari, S.; Giannopoulos, K.; Hernandez-Rivas, J. M.; Kohlmann, A.; Morgan, M.; Porse, B.; Tagliafico, E.; Zwaan, C. M.; Wainscoat, J.; Van den Heuvel-Eibrink, M. M.; Mills, K.; Bullinger, L. // Leukemia (08876924);Jun2011, Vol. 25 Issue 6, p909 

    Today, the classification systems for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) already incorporate cytogenetic and molecular genetic aberrations in an attempt to better reflect disease biology. However, in many MDS/AML patients no genetic aberrations have been identified...

  • Acute Myeloid Leukemia with a Masked Type of Three-Way t(8;11;21) Revealed by Fluorescence In Situ Hybridizations Using AMLI-ETO Probe. Trivedi, Pina J.; Brahmbhatt, Manisha M.; Patel, Dharmesh M.; Shukla, Shilin N.; Patel, Prabhudas S. // Journal of the Association of Genetic Technologists;2014 First Quarter, Vol. 40 Issue 1, p11 

    The translocation (8;21)(q22;q22) is associated with acute myeloblastic leukemia (AML) with M2 subtype. The accurate detection of this chromosomal rearrangement is vital due to its association with a favorable prognosis. Variants of t(8;21)(q22;q22) involving chromosomes 8, 21 and other...

  • Philadelphia Chromosome-Positive Acute Myeloid Leukemia: A Rare Aggressive Leukemia With Clinicopathologic Features Distinct From Chronic Myeloid Leukemia in Myeloid Blast Crisis. Chad Soupir; Jo-Anne Vergilio; Paola Cin; Alona Muzikansky; Hagop Kantarjian; Dan Jones; Robert Hasserjian // American Journal of Clinical Pathology;Apr2007, Vol. 127 Issue 4, p642 

    We performed a multi-institutional retrospective analysis of the morphologic features, immunophenotype, cytogenetics, and BCR-ABL transcript characterization of cases of Philadelphia chromosome-positive acute myeloid leukemia (Ph+ AML). We compared these cases with cases of documented chronic...

  • Detection of BCR-ABL by quantitative PCR did not jeopardize CCyR in CML.  // Hem/Onc Today;2/10/2009, Vol. 10 Issue 3, p18 

    The article focuses on a clinical trial which examined the effects of increases in BCR-BL transcript by quantitative polymerase chain reaction (QPCR) on complete cytogenetic response in chronic myeloid leukemia.

  • TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Lorsbach, R B; Moore, J; Mathew, S; Raimondi, S C; Mukatira, S T; Downing, J R // Leukemia (08876924);Mar2003, Vol. 17 Issue 3, p637 

    Leukemia (2003) 17, 637-641. doi:10.1038/sj.leu.2402834

  • Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8. Becker, H; Maharry, K; Mrózek, K; Volinia, S; Eisfeld, A-K; Radmacher, M D; Kohlschmidt, J; Metzeler, K H; Schwind, S; Whitman, S P; Mendler, J H; Wu, Y-Z; Nicolet, D; Paschka, P; Powell, B L; Carter, T H; Wetzler, M; Kolitz, J E; Carroll, A J; Baer, M R // Leukemia (08876924);Aug2014, Vol. 28 Issue 8, p1754 

    A letter to the editor is presented which discusses clinical and molecular characterization of adults with de novo acute myeloid leukemia (AML) and sole +8 cytogenetic abnormality enrolled on Cancer and Leukemia Group B/Alliance clinical trials.

  • Long-term follow-up of cytogenetically normal CEBPA-mutated AML. Pastore, Friederike; Kling, Daniela; Hoster, Eva; Dufour, Annika; Konstandin, Nikola; Schneider, Stephanie; Sauerland, Maria; Wolfgang, Berdel; Buechner, Thomas; Woermann, Bernhard; Braess, Jan; Hiddemann, Wolfgang; Spiekermann, Karsten // Journal of Hematology & Oncology;2014, Vol. 7 Issue 1, p1 

    Background The aim of this study was to analyze the long-term survival of AML patients with CEBPA mutations. Patients and methods We investigated 88 AML patients with a median age of 61 years and (1) cytogenetically normal AML (CN-AML), (2) monoallelic (moCEBPA) or biallelic (biCEBPA) CEBPA...

  • Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes. Matsui, W. H.; Brodsky, R. A.; Smith, B. D.; Borowitz, M. J.; Jones, R. J. // Leukemia (08876924);Mar2006, Vol. 20 Issue 3, p458 

    Aplastic anemia (AA) and hypoplastic myelodysplastic syndromes (hMDS) are often difficult to distinguish. However, an accurate diagnosis is important because the prognosis and treatment of these diseases may differ. CD34+ hematopoietic progenitors are central to the pathogenesis of both...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics